AbbVie shells out $440M on two PRVs for label expansions of its blockbuster Rinvoq

The priority review voucher market can be notoriously secretive, especially when companies purchase PRVs and don’t disclose where they’re planning to use the expedited FDA reviews.

For AbbVie, that strategy has been plain and simple so far: Expand blockbuster Rinvoq’s label as quickly as possible.

Back in 2015, the Chicago-based...

Click to view original post